<i id='0E0F74B5B0'><strike id='0E0F74B5B0'><tt id='0E0F74B5B0'><pre id='0E0F74B5B0'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Psychedelics group wrestles with new pharma identity 
In diabetes hearing, Sanders takes on a new foe: food makers 
Moonlake's readout produced a cash windfall. Risks remain 
Pfizer plans to depart BIO 
Apple is now the first public company to be valued at $3 trillion 
SCOTUS to consider access to abortion pill mifepristone 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal 
Continuity nursing helped my family in our darkest PICU moments 
FDA approves world's first CRISPR 
Walensky prepares to leave CDC — and Congress — behind 
STAT Summit: How researchers deal with rejection 
How to save PrEP access — and even expand it 
Roche to buy Carmot Therapeutics, developer of obesity drugs 
Affirmative action in medical school literally saved lives 
